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Abstract: Background and Objectives: In patients with inflammatory bowel diseases (IBD), the use of 
azathioprine results in adverse events at a rate of 5% to 20%. The aim of the study was to assess a 
possible correlation between genetic variability of the enzyme thiopurine S-methyltransferase 
(TPMT) and the development of toxicity to azathioprine. Materials and Methods: A retrospective, 
single center, blind, case-control study was conducted on 200 IBD patients, of whom 60 cases 
suspended azathioprine due to toxicity (leukopenia, pancreatitis, hepatitis, and nausea or 
vomiting), and 140 controls continued treatment with the drug without adverse events. Results: In 
the entire cohort, only 8 cases of heterozygous mutations of TPMT were observed, corresponding 
to 4% mutated haplotype rate, much lower than that reported in literature (close to 10%). No 
homozygous mutation was found. Regarding the TPMT allelic variants, we did not find any 
statistically significant difference between patients who tolerated azathioprine and those who 
suffered from adverse events. (OR = 0.77, 95% CI = 0.08–7.72; p = 0.82). Conclusions: According to our 
study, in IBD patients, the search for TPMT gene mutations before starting treatment with 
azathioprine is not helpful in predicting the occurrence of adverse events. Importantly, patients with 
allelic variants should not be denied the therapeutic option of azathioprine, as they may tolerate 
this drug. 
Keywords: Crohn’s disease; inflammatory bowel disease; large intestine; small intestine; ulcerative 
colitis 
 
1. Introduction 
The inflammatory bowel diseases (IBD) include Crohn’s disease (CD) and ulcerative colitis (UC), 
both characterized by chronic and uncontrolled inflammation of the intestinal mucosa.  
Thiopurines, mainly represented by 6-mercaptopurine and the prodrug azathioprine, are used 
in cases of steroid-dependent IBD or to reduce the risk of recurrence after surgery in CD [1,2], as they 
have cytotoxic and immunosuppressive properties [3]. Therefore, 15–28% of patients on treatment 
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with thiopurines have several adverse reactions; mainly gastrointestinal intolerance, and 
hematological, hepatic, and pancreatic effects [4]. 
Once inside the cell, azathioprine is converted to 6-mercaptopurine by glutathione-S-transferase 
and undergoes several metabolic transformations that lead to the production of two different active 
nucleosides: The conversion of 6-mercaptopurine by the enzyme hypoxanthine guanine 
phosphoribosyltransferase leads to the formation of 6-thioguanine (6-TG), and the thiopurine methyl-
transferase (TPMT) pathway leads to the methylation of 6-mercaptopurine, forming 6-methyl-
mercaptopurine riboside (6-MMPr) [3]. These metabolites have some differences in their effect on 
target cells: The current opinion is that 6-TG may be responsible for the immunosuppressive effect, 
while 6-MMPr may be a secondary metabolic product (dependent on TPMT activity) with a less 
effective action, but a stronger toxic effect on the liver [5]. Thus, an overproduction of 6-TG could 
lead to myelosuppression (due to excessive effect), while an overproduction of 6-MMPr could lead 
to hepatotoxicity [6]. The activity of TPMT has wide inter-individual variability. Weinshilboum et al. 
[7], in a randomized study including 298 patients, showed that TPMT activity has a bimodal 
distribution in the general population: Approximately 89% have high enzymatic activity, 11% 
intermediate activity, and only 1 out of 300 (0.3%) lack activity. Such variability is partially 
determined by single nucleotide polymorphisms (SNPs) in the TPMT gene [8]. Four allelic variants, 
called TPMT*2, *3B, *3C and *3A (resulting from the association of mutations *3B and *3C), were 
found in more than 80% of Caucasian subjects with a middle or low enzymatic activity, of which the 
most frequent was *3A [9]. Patients with TPMT*3A mutations have a complete loss of enzymatic 
activity, those with TPMT*3B exhibit a 9-fold reduction in enzyme activity, while in patients with 
TPMT*3C, enzyme activity falls by 1.4%. In the United States, the Food and Drug Administration has 
suggested the genetic typing of TPMT before starting azathioprine or 6-mercaptopurine treatment to 
prevent myelotoxicity [10]. 
The aim of this study was to evaluate the potential correlation between the genetic variability of 
TPMT and the development of toxicity associated with azathioprine treatment in patients with IBD. 
2. Materials and Methods 
We included patients with IBD who were followed at the outpatient clinic of the Unit of 
Gastroenterology, A.O.U. City of Health and Science of Turin, between June 2015 and January 2016. 
All patients received written information on the study and gave signed informed consent for blood 
testing and clinical data collection. The study followed the principles of the Declaration of Helsinki 
and was approved by the local ethical committee (Comitato Etico Interaziendale A.O.U. Città della 
Salute e della Scienza di Torino—A.O. Ordine Mauriziano—A.S.L. Città di Torino) (approval code 
0056825). 
In all patients, azathioprine dosage was increased throughout the study (initially 0.5–1 mg/kg 
daily, then increased over 3–4 weeks to 2.0–2.5 mg/kg daily). 
After obtaining written informed consent, patients were divided in two classes: Those who had 
stopped azathioprine therapy due to toxicity (cases), and those who continued azathioprine 
treatment (2.0–2.5 [mg/kg]) for at least 4 months without adverse events (controls). 
The inclusion criteria were CD or UC diagnosed according to European Crohn’s and Colitis 
Organization (ECCO) criteria [1,11]. The exclusion criteria were: Start of a new medical therapy for 
IBD during azathioprine treatment; positive history of hematologic, hepatic, gallbladder or 
pancreatic diseases; alcohol consumption of more than 20 g/day; and lack of signed informed consent. 
Among patients who suspended azathioprine due to toxicity; pancreatitis, hepatitis, leukopenia 
and gastrointestinal intolerance were reported as side effects. Pancreatitis was defined in the presence 
of clinical symptoms (abdominal pain which may radiate to the back, often associated with nausea 
and vomiting, and elevation of serum amylase three times above the upper limit) [12]. Abdominal 
ultrasound was performed to rule out biliary pancreatitis. Toxic hepatitis was diagnosed in the 
presence of an elevation of alanine transaminase (ALT) or aspartate aminotransferase (AST) levels ≥2 
times the upper limit [13], whereas leukopenia was detected through a white blood cell count of less 
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than 3.0 [× 109/L]. Gastrointestinal intolerance was defined as the new onset of nausea and/or 
vomiting without abdominal pain and serum alterations of pancreatic/liver enzymes. 
A peripheral venous blood sample was taken from all patients to obtain DNA for TPMT 
genotyping, which was performed blinded to the adverse events. The three most common allelic 
variants of the TPMT gene (TPMT*2, TPMT*3C and TPMT*3B) in the Caucasian population were 
analyzed. TPMT enzyme genotyping and evaluation of its allelic variants TPMT*2, *3A, *3B, *3C 
involved: Extraction and quantification of DNA; mutations identification of G238C (TPMT*2), G460A 
(TPMT*3B), A719G (TPMT*3B); amplification by means of Polymerase Chain Reaction Restriction 
Fragment Length Polymorphism (PCR-RFLP); and evaluation of allelic variants of the TPMT gene. 
Based on the genotype of the TPMT enzyme, subjects were later characterized as wild-type 
homozygotes (TPMTW/TPMTW), heterozygotes (TPMTW/TPMTM), or mutated homozygotes 
(TPMTM/TPMTM). 
The differences in the allelic frequencies between the respective groups were analyzed by 
Fisher’s exact test, considering statistical significant as p < 0.05. Data were presented as allelic 
frequencies and percentages in the respective groups. From the contingency tables, calculations of 
the odds ratio (OR) and confidence interval (CI) at 95% were performed. The statistical analysis was 
performed by using MedCalc software (version 14.8.1). 
3. Results 
Among the 2427 patients affected by IBD who were followed regularly at our outpatient clinic, 
702 were on active treatment or had been previously treated with azathioprine. Of these, 472 were 
excluded because of concomitant therapy with azathioprine (193), because they had a positive history 
of hematologic, hepatic, gallbladder, or pancreatic disease (129), or because they had an alcohol 
consumption of more than 20 g/day (150). Of the remaining 230 patients, 30 refused to participate in 
the study.  
Thus, 200 patients suffering from IBD were selected, including 60 cases (30%) who had stopped 
azathioprine therapy due to toxicity, and 140 controls (70%) on stable azathioprine treatment. Of the 
whole population, 120 (60%) were affected by CD and 80 (40%) by UC. The clinical characteristics of 
CD patients and UC patients are reported in Table 1. 
Table 1. The clinical characteristics of the UC patients (n = 80) and CD patients (n = 120). 
 UC Patients CD Patients 
Sex, n (%)   
Males 48 (60) 68 (57) 
Females 32 (40) 52 (43) 
Age at diagnosis (mean age, range) 33 (13–59) 30.5 (16–67) 
Azathioprine therapy n (%)   
Ongoing 56 (70) 84 (70) 
Stopped for adverse events 24 (30) 36 (30) 
Average time azathioprine is ongoing (months) 69 59 
 
The most common side effect in patients who had to stop azathioprine was pancreatitis; 
representing 47% of total adverse events, followed by toxic hepatitis (40% of the total). Leukopenia 
was found in six cases (10%), and only two cases (3%) of gastrointestinal intolerance were reported 
(Table 2).  
Table 2. Adverse events which led to the stopping of azathioprine therapy, and the TPMT genotype 
in patients. 
Adverse Event, n (% among Patients who have Stopped Azathioprine Therapy 
due to Toxicity) 
TPMT Genotype (Number of 
Patients) 
Pancreatitis, 28 (47) 
*1/*1 (26) 
*1/*3A (2) 
Hepatitis, 24 (40) *1/*1 (24) 
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Leukopenia, 6 (10) *1/*1 (6) 
Nausea and vomiting, 2 (3) *1/*1 (2) 
*1/*1 = homozygous wild type genotype; *1/*3A = heterozygous genotype. 
Among the 60 cases only 2 (3%) showed a heterozygous mutation (*3A). Among the 140 controls, 
a wild-type (*1/*1) genotype was found in 134 (96%), while 6 (4%) were found to carry a mutation in 
heterozygosity; 4 (3%) with genotype *3A and 2 (1%) with genotype *2. No mutation on both alleles 
(homozygous mutation) was observed. 
When comparing cases with controls, no statistically significant difference was found. A 
frequency of allelic variants of 3% (2/60 patients) and 4% (6/140 patients) were detected in cases and 
controls, respectively (p = 0.824). No allelic variant was associated with adverse events related to 
azathioprine treatment (OR = 0.77, 95% CI = 0.08–7.7; p = 0.82). Moreover, no allelic variant was found 
in patients with leukopenia, hepatitis, or nausea and vomiting. 
Considering the pancreatitis side effect alone, no statistically significant difference was found 
between the frequency of haplotype mutation in patients with pancreatitis compared to those who 
did not develop it: 7.1% (2/28 patients) and 3.5% (6/172 patients), respectively. No statistically 
significant correlation was found between TPMT gene mutation and azathioprine-induced 
pancreatitis (OR 2.1, 95% CI 0.2–22; p = 0.53). We did not find any statistically significant correlation 
between TPMT gene mutations and gender (4 out of 116 males, 3.4%, 4 out of 84 females, 4.8%; p = 1) 
or IBD type (2 out of 120 CD, 1.7%, 6 out of 80 UC, 7.5%; p = 0.3). The differences in the allelic 
frequencies among the respective groups and relative odds ratios with their 95% CIs are showed in 
Table 3. 
Table 3. Allelic frequencies among the respective groups and relative odds ratios with their 95% 
Cis. 
 
Overall 
Toxicity 1 Pancreatitis 
2 Gender 3 Disease 4 
 Yes No Yes No Males Females CD UC 
Mutated 2 6 2 6 4 4 2 6 
Wild-Type 58 134 26 166 112 80 118 74 
Total 60 140 28 172 116 84 120 80 
1 OR = 0.77; 95% CI = 0.08–7.7; p = 0.82; 2 OR = 2.1; 95% CI = 0.2–22; p = 0.53; 3 OR = 0.72; 95% CI = 0.18–
2.98; p = 1; 4 OR = 0.2; 95% CI = 0.04–1.81; p = 0.3. 
4. Discussion 
The crucial question as to whether pretreatment TPMT testing performed in IBD patients 
contributes to decreasing bone marrow suppression-specific mortality induced by azathioprine has 
long been a matter of debate [14,15]. In a multicenter study, thiopurine therapy was prescribed either 
according to the classic therapeutic dosage, or the dose adjusted according to the TPMT mutations: 
The overall proportion of hematological adverse events did not differ between the groups [16]. 
In our study comprising of 200 patients, a heterozygous mutation was found in only eight 
patients, corresponding to a 4% frequency of mutated haplotypes. This is significantly lower than the 
rate reported in the literature (close to 10% [17]), despite the high frequency of adverse events 
registered in our population. The latter is due to the fact that our study design focused on patients 
with adverse events. We selected 60 cases that suspended azathioprine due to adverse events. This 
sample (30% of the study population) is not comparable with the data of any prospective studies that 
report lower frequencies of adverse events, especially regarding pancreatitis occurrence [18]. 
Moreover, myelotoxicity often appears after several months of therapy, thus a study period of 4 
months could underestimate the myelotoxicity rate, although in the literature leukopenia is reported 
as an early side effect.  
According to ECCO guidelines [1,2], among the 60 patients with adverse events, azathioprine 
therapy was stopped. However, it should be noted that in patients with hepatotoxicity, a potential 
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alternative for overcoming intolerance could be treatment with low-dose azathioprine plus 
allopurinol. In our context, we had to choose the option of stopping treatment due to the patients’ 
disagreement to continue the same drug.  
In six out of eight cases, the *3A heterozygous mutation was found (the most common in 
Caucasian subjects [3]) while in two out of eight, the *2 heterozygous mutation was found. No 
homozygous mutation has been found in any subject. 
The statistical analysis showed no significant difference between those who tolerated 
azathioprine and those who had overall adverse events regarding the frequency of the allelic variants 
of TPMT (OR = 0.77; 95% CI 0.08–7.71; p = 0.82). In addition, no statistically significant difference was 
observed in the rate of haplotype mutation among patients who developed pancreatitis compared to 
those who did not develop it (7.1%, 2/28 patients, and 3.4%, 6/172 patients, respectively; p = 0.53). This 
is in line with data reported in other studies [19,20]. When considering the type of toxicity, no 
correlation was found between the TPMT genotype and the development of leukopenia, 
hepatotoxicity, or nausea and vomiting. Finally, no statistically significant differences were found 
between the groups obtained by stratification based on gender (p = 1) or type of IBD (p = 0.3), when 
comparing the frequency of the allelic variants of TPMT. 
A meta-analysis investigated the associations between TPMT polymorphisms and azathioprine-
induced adverse events in patients with autoimmune diseases [21]. The results showed that TPMT 
polymorphisms were significantly associated with azathioprine-induced overall adverse effects, 
bone marrow toxicity, and gastric intolerance. However, the subgroup analysis according to ethnicity 
showed a significant association between TPMT polymorphisms and azathioprine-induced bone 
marrow toxicity in Asian populations, but not in Caucasian populations. The authors concluded that 
TPMT polymorphisms can explain a variable proportion but not all episodes of azathioprine-related 
adverse events, and furthermore, a normal TPMT genotype cannot exclude the development of side 
effects. Thus, TPMT genotyping before starting azathioprine therapy cannot replace the current 
practice of periodic monitoring of white blood cell count. We agree with the authors’ conclusions 
and, according to our data, the search for TPMT gene mutations before starting azathioprine therapy 
is not useful to predict adverse events such as leukopenia, pancreatitis, hepatitis, or nausea and 
vomiting. The exclusion of patients with TPMT allelic variants could also deny a therapeutic option 
to about 4% of those who may tolerate such drug. 
Other methods have been studied to detect rare or novel variants of genes accounting for 
thiopurine toxicity, which are not detectable through standard genotyping, and although a significant 
association between TPMT activity and some of these variants has been reported, there is no clear 
advantage over biochemical monitoring for predicting toxicity [22]. 
A potential limitation of our study is its retrospective nature. However, the potential 
heterogeneity arising from this is limited by the fact that, in our outpatient clinic, all authors follow 
International Guidelines [1,2]. Furthermore, during the past 25 years, all consultations have been 
recorded in both a paper archive and a computerized data bank. Lastly, the case-control design [3] is 
adequate to find a difference in an objective parameter like a haplotype variant between patients who 
stopped azathioprine due to an adverse event, and those who tolerated it for a mean time of more 
than 60 months. Another potential limitation of our study is that, to date, 31 allelic variants (TPMT*2–
TPMT*29) are known to be associated with a poor enzymatic activity, compared to the wild-type 
allele (TPMT*1), and in our study, 4 allelic variants (TPMT*2, *3B, *3C and *3A) were sought. We 
considered these variants as they are found in more than 80% of Caucasian subjects with middle or 
missing enzymatic activity [9]. However, this choice could explain the lower frequency of mutated 
haplotypes detected in our cohort (4%), compared with that reported in the literature (10%) [17]. 
Furthermore, metabolite levels of 6-TG and 6-MMP were not measured. 
5. Conclusions 
Our results support the ECCO guidelines that do not recommend performing the genetic typing 
of TPMT before thiopurine therapy is initiated, and suggest close laboratory monitoring, including 
complete blood count, and pancreatic and hepatic biochemistry. 
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